Term ends Dec 28, 2032 · High confidence
20-year base term ends Dec 28, 2032
Held by Global Blood Therapeutics, Inc.
Filed Dec 22, 2017 as application 15/852,406 · Granted Jul 31, 2018
Base term, 20 years from filing
Today
2012
2032
Clock starts
Dec 28, 2012
Dec 28, 2012
Term ends
Dec 28, 2032
Dec 28, 2032
Granted
Jul 31, 2018
Jul 31, 2018
base term
fee events
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,017,491, US 9,018,210, to Dec 28, 2032. The term already ends on or before that date, so the cap shortened nothing.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
10
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 28, 2012, when application 13/730,674, the earliest non-provisional in its chain, was filed (this one was filed Dec 22, 2017) | Dec 28, 2032 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,017,491, US 9,018,210) | resolves to Dec 28, 2032, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Dec 28, 2032 | High confidence |
This family
| US 9,018,210 | In force Nov 2033 | Nov 2033 |
| Application 14/662,156 | Abandoned not computed | not computed |
| Application 15/081,704 | Abandoned not computed | not computed |
| US 10,034,879 | this patent Dec 2032 | Dec 2032 |
| US 10,806,733 | In force Dec 2032 | Dec 2032 |
| Application 17/068,306 | Abandoned not computed | not computed |
| Application 17/334,213 | Abandoned not computed | not computed |
| Application 17/571,183 | Abandoned not computed | not computed |
8 of 10 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jan 11, 2018 Reel 44603, frame 447 | Metcalf, Brian | Global Blood Therapeutics, Inc. | Assignment of Assignor's Interest |
| Mar 15, 2018 Reel 45238, frame 111 | Chuang, Chihyuan | Cytokinetics, Inc. | Assignment of Assignor's Interest |
| Mar 15, 2018 Reel 45238, frame 138 | Cytokinetics, Inc. | Global Blood Therapeutics, Inc. | Assignment of Assignor's Interest |
| May 1, 2018 Reel 46050, frame 266 | Cytokinetics, Inc. | Global Blood Therapeutics, Inc. | Confirmatory Assignment |
| Dec 20, 2019 Reel 51396, frame 312 | Global Blood Therapeutics, Inc. | Biopharma Credit PLC | Security Interest |
| Dec 9, 2020 Reel 54664, frame 871 | Global Blood Therapeutics, Inc. | Biopharma Credit PLC | Amended and Restated Patent Security Agreement |
| Dec 22, 2021 Reel 58575, frame 921 | Global Blood Therapeutics, Inc. | Biopharma Credit PLC | Second Amended and Restated Patent Security Agreement |
| Oct 6, 2022 Reel 61620, frame 186 | Biopharma Credit PLC, as Collateral Agent | Global Blood Therapeutics, Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Dec 2032
Term ends Dec 28, 2032. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 10,017,491, US 9,018,210, ends no earlier than this term, so it caps nothing.
Citations
35
later US patents cite this one
That is top 10% of utility patents granted in 2018 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.